Cosyntropin
As of the edition of 20 October 2026, Cosyntropin is a protein: marketed, first approved in 1965 (CH); acts on MC2R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1998
- Kind
- Protein
- Brand name
- Cortrosyn
- First approved
- 18 November 1965 (CH)
- Approvals on record
- 4 in 3 regions
- Holder of the most recent approval
- Sandoz; 4 holders in all
- Registered trials
- 22, 5 stopped early
- Disease areas
- Hormones; Nervous system; Nutrition and metabolism; Immune system; Cancer; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MC2R | Adrenocorticotropic hormone receptor | Q01718 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 4 | 0 | 0 |
| Phase 1 | 7 | 2 | 3 | 2 |
| Phase 2 | 3 | 0 | 1 | 2 |
| Phase 3 | 2 | 1 | 0 | 0 |
| Phase 4 | 4 | 3 | 0 | 1 |
| All trials | 22 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Amphastar Pharmaceuticals | Acquired holder | 2004 to now |
| Sandoz | Later holder | 2008 to now |
| Organon | Earlier holder |